Incretin research
Retatrutide vs Semaglutide
Retatrutide against a familiar GLP-1 reference point.
Overview
This comparison separates Retatrutide and Semaglutide for laboratory reference—not product selection.
Retatrutide: Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the highest recorded for obesity medi…
Semaglutide: Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant efficacy through appetit…
Differences
- Retatrutide is discussed across GLP-1, GIP, and glucagon receptors.
- Semaglutide functions here as a GLP-1 reference—not an AXIOM catalogue item.
Mechanism
Retatrutide: Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the highest recor…
Semaglutide: Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant effi…
Pharmacology
Retatrutide: Pharmacokinetic detail should be read from primary literature.
Semaglutide: Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant effi…
Research
Retatrutide: GLP-1 & metabolic: Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the high…
Semaglutide: GLP-1 & metabolic: Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated signifi…
Summary
Distinction
- AXIOM does not provide dosing, administration, or protocol guidance.
- Catalogue links appear only where AXIOM lists a research-use product.
- Reference-only compounds remain comparison terms without implying availability.
References
- pubmed.ncbi.nlm.nih.gov/37366315/
- pubmed.ncbi.nlm.nih.gov/40609566/
- pubmed.ncbi.nlm.nih.gov/41090431/
- pubmed.ncbi.nlm.nih.gov/39019866/
- pubmed.ncbi.nlm.nih.gov/37385280/
- pubmed.ncbi.nlm.nih.gov/38858523/
- pubmed.ncbi.nlm.nih.gov/40305708/
- pubmed.ncbi.nlm.nih.gov/33567185/
Questions
Does this page recommend Retatrutide or Semaglutide?
No. It is an editorial comparison for research context only.
Does AXIOM provide protocol guidance?
No. Protocol and dosing decisions belong with qualified laboratory teams and source literature.
Available from AXIOM
Catalogue
Labelled strengths and batch records where available.